Harrow terminates $18.4M Melt loan, takes ~47% equity stake; appoints Saharek division president

HARROW, INC.

Terminated Loan Agreement with Melt; received 2.26M Series B-1 and 74k Series B preferred shares in full settlement of ~$18.4M outstanding.
After settlement, Harrow holds ~47% of Melt's equity (including 3.5M common shares) plus royalty rights on Melt drug candidates.
John P. Saharek appointed President/CEO of ImprimisRx division effective Jan 2, 2024; base salary $450K, target bonus 50%.
Melt received FDA support for MELT-300 Phase 3 program; expects to begin Phase 3 in Q1 2024, potentially benefiting Harrow's stake.
Code of Business Conduct and Ethics amended to update corporate name and clarify political activities; no waivers granted.

item 1.02 item 8.01 item 5.02 item 5.05 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

John P. Saharek

President and Chief Executive Officer of the Company's ImprimisRx division

HROW · HARROW, INC.

Effective: 2024-01-02
Filed: January 3, 2024, 6:59 PM ET

Effective January 2, 2024, Harrow, Inc. (the “Company”) appointed John P. Saharek as the President and Chief Executive Officer of the Company’s ImprimisRx division, in addition to his current role as Chief Commercial Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

John P. Saharek was appointed as President and Chief Executive Officer of the Company's ImprimisRx division at HARROW, INC..

Action: appointed
Role: President and Chief Executive Officer of the Company's ImprimisRx division

Exact text from the filing

Effective January 2, 2024, Harrow, Inc. (the “Company”) appointed John P. Saharek as the President and Chief Executive Officer of the Company’s ImprimisRx division, in addition to his current role as Chief Commercial Officer of the Company.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

HARROW, INC.: Amendments to the Code of Business Conduct and Ethics to update corporate name and clarify obligations regarding political activities (effective 2023-12-28).

Change: code of ethics
Effective: 2023-12-28

Exact text from the filing

Effective December 28, 2023, the Board of Directors of the Company approved certain amendments to the Company’s Code of Business Conduct and Ethics (the “Code”) upon the recommendation of the Nomination and Corporate Governance Committee of the Board.

View on SEC.gov

188 governance changes filed in the last 30 days. Browse all governance changes →

HARROW, INC. filing history →

Source: SEC EDGAR

accession 0001493152-24-000192

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.